FUSION ANTIBODIES PLC (FAB) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the FUSION ANTIBODIES PLC investor presentation. During this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press end. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Adrian Kincaid, CEO. Good afternoon, sir. Thank you very much, Lily. Thank you everyone for joining us today. It's good to see the back end of the year that we've got to talk about, but we'll also be covering some of the more recent data. There is another quarter that's already in the public domain. So without any further ado, we'll move on. Of course, we have disclaimer, which I will leave you to read at your your leisure. Thank you very much. What we'll do on the agenda is cover some introduction and highlights, particularly for people who maybe haven't got too familiar with FUSION as yet. We'll do some financial performance slides, which will be led by by Steven, and then strategic focus update, which I'll cover, and a short summary. We have had some questions already submitted, so it's good to see the engagement. Thank you very much once again. So as an introduction to FUSION ANTIBODIES, I should introduce myself first. It's I'm Adrian Kincaid. I'm CEO of FUSION ANTIBODIES. Been with the with the company now for just over two years. I'm a biochemist by training. I have a PhD in biochemistry from Southampton University and have been in ph...